Top News
How Celltrion’s Truxima Dominates the U.S. Rituximab Market: A 4-Month Winning...
Celltrion's Truxima leads the U.S. rituximab market for four months, gaining FDA interchangeability status, boosting growth prospects.
- Our Sponsors Ad -